Pancreatic Cancer Drugs Market Report 2025

The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.96 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer.

The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support. Major trends in the forecast period include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.

The anticipated growth of the pancreatic cancer drugs market is driven by the increasing prevalence of pancreatic cancer. The elevated number of pancreatic cancer cases is expected to boost the demand for drugs, consequently fueling market growth. The surge in cancer instances is largely attributed to factors such as an aging population and a growing number of people dealing with obesity. For example, the American Cancer Society estimates that in 2023, approximately 64,050 individuals (33,130 men and 30,920 women) will receive a pancreatic cancer diagnosis, and about 50,550 people (26,620 men and 23,930 women) will succumb to pancreatic cancer.

Government initiatives and funding aimed at pancreatic cancer research are expected to significantly drive the growth of the pancreatic cancer drugs market in the coming years. These initiatives provide financial support to entities focused on projects that enhance public health and improve patient outcomes. For example, in June 2024, the National Institutes of Health, a US-based government agency, reported an increase in funding for pancreatic cancer research, rising from an estimated $218.1 million in 2021 to $226.8 million in 2022. This boost in financial support underscores the government's commitment to improving the quality of life and survival rates for patients affected by pancreatic cancer, thereby fostering advancements in drug development and treatment options within the market.

An ongoing trend in the pancreatic cancer drugs market is the preference for combination therapy over monotherapy. Recognizing the potential to enhance drug efficacy and improve the survival rates of patients with pancreatic cancer, major players in the market are increasingly exploring the combination of two or more drugs. Companies such as Rafael Pharmaceuticals have initiated pivotal Phase 3 trials, such as AVENGER 500, combining CPI-613 (delimitate) with Modified FOLFIRINOX as a first-line treatment for patients with Metastatic Pancreatic Cancer. Apexigen, Inc., a clinical-stage biopharmaceutical company, is also investing in combination therapy, presenting new clinical data on APX005M for patients with metastatic pancreatic cancer.

To gain a competitive edge, major companies in the pancreatic cancer drugs market are investing in local drug delivery systems. This approach involves administering drugs directly to the site of action, enhancing efficacy while minimizing side effects. For instance, OncoLize, a Netherlands-based company, raised a US$ 1.7 million seed investment round in April 2023 to extend their preclinical success with a local drug delivery system for treating pancreatic and lung cancer. This innovative product utilizes unique liquid formulations to deliver a variety of anti-cancer drugs more effectively, both traditional chemotherapy drugs and modern immuno-drugs.

In October 2022, Pfizer Inc., a prominent US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for an undisclosed amount. This strategic acquisition is part of Pfizer's efforts to enhance its portfolio with innovative migraine treatments, particularly focusing on CGRP receptor antagonists such as NURTEC ODT and zavegepant. With an aim to tap into the substantial revenue potential in the migraine market - projected to exceed $6 billion - this move aligns with Pfizer's broader strategy to expand its internal medicine pipeline through 2030 and beyond. Biohaven Pharmaceuticals is known for its expertise in developing novel treatments, including antibody-drug conjugates for various conditions, which complements Pfizer's growth objectives in the pharmaceutical landscape.

Major companies operating in the pancreatic cancer drugs market include Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd, Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt Ltd, Apikos Pharma, GlaxoSmithKline Plc, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer AG, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology.

North America was the largest region in the pancreatic cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Pancreatic cancer drugs refer to medications designed for treating pancreatic cancer, a condition resulting from uncontrolled cell growth in the pancreas. This abnormal growth disrupts the pancreas' production of digestive juices and hormones responsible for regulating blood sugar levels. Tissue lumps, known as tumors, develop due to this excessive cell growth, impeding the normal functioning of the pancreas.

Pancreatic cancer drugs can be categorized into two main types endocrine pancreatic cancer and exocrine pancreatic cancer. Exocrine pancreatic cells generate enzymes released into the small intestine to aid in the digestion of food as it traverses the digestive tract. The diverse range of drugs for pancreatic cancer treatment includes Afinitor, erlotinib, hydrochloride everolimus, 5-FU (fluorouracil), gemcitabine, and Abraxane. These drugs find application in various healthcare settings, including hospitals, clinics, and others.

The pancreatic cancer drugs market research report is one of a series of new reports that provides pancreatic cancer drugs market statistics, including pancreatic cancer drugs industry global market size, regional shares, competitors with a pancreatic cancer drugs market share, detailed pancreatic cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer drugs industry. This pancreatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer drugs market consists of sales of Gemcitabine (Gemzar), 5-fluorouracil (5-FU), and Irinotecan (Camptosar). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.